IMR Press / EJGO / Volume 5 / Issue 2 / pii/1984014

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research

A french double-blind crossover study (danazol versus placebo) in the treatment of severe fibrocystic breast disease

Show Less
1 Hopital Saint-Louis38, Rue Bichat 75010, Paris, France
2 University Paris VII, Paris, France
Eur. J. Gynaecol. Oncol. 1984, 5(2), 85–89;
Published: 10 June 1984

The Authors report their experience in a double-blind, crossover study (danazol versus placebo) in 38 patients suffering from severe benign mastopathy. The results were evaluated with regard to clinical data (mastodynia, breast nodularity) and data from comparative infrared thermography. Danazol was given in a dose of 400 mg/day for 3 months. Placebo, in identical packing, was also given for a three month period. In 32 cases out of 38, there was an improvement with Danabol treatment. For some patients, thermography was more precise than clinical part. Side effects consisted predominantly of men­strual disorders recorded in 30 cases and a generally moderate weight gain in 23 cases. In the light of these results it appears that danazol constitutes a powerful agent in the treatment of severe benign mastopathy of the breast. The best dosage and best duration of treatment remain to be specified. Finally, the original contribution of the thermographic documenst deserves to be underlined.

Breast disease
Back to top